Pocket guide: biologics in upper and lower airways in adults
Volume: 63 - Issue: 2
First page: 242 - Last page: 244
W.J. Fokkens - V. Backer - V.J. Lund - P.J. Barnes - M. Bernal-Sprekelsen - L. Bjermer - E. de Corso - D.M. Conti - M.E. Cornet - Z. Diamant - R. Djukanovic - M. Gaga - P. Gevaert - J.K. Han - C. Hopkins - G. Joos - B.N. Landis - S. Lau - S.E. Lee - J. Mullol - A.T. Peters - G.K. Scadding - S. Schneider - B. Senior - I.D. Pavord - S. Quirce - D. Ryan - M.E. Wechsler - P.W. Hellings
DOI: 10.4193/Rhin24.510
The introduction of biologics for the treatment of severe upper and lower (type 2) airway inflammation has been a game changer in the management of these diseases. Biologics are injectable medications targeting different molecules relevant in (type 2) inflammation in patients with severe (type 2) airway diseases, like asthma, eosinophilic chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis (CRS) and those who remain uncontrolled despite regular treatment. After the phase 3 trials, showing significant impact on symptoms, quality of life and interventions like surgery (for the upper airways) and exacerbations needing hospitalisation (for the lower airways), biologics are now used in daily practice in many parts of the world. This pocket guide is aimed at all specialists treating adult patients
with severe airway disease.
Rhinology 63-2: 242-244, 2025
To see the issue content and the abstract you do not have to login
Please login to download the full articles
If you do not have a subscription to Rhinology please consider taking one.
